| scholarly article | Q13442814 |
| P2093 | author name string | Michael S Rafii | |
| Paul S Aisen | |||
| P2860 | cites work | A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline | Q22251083 |
| Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 | ||
| The amyloid hypothesis of Alzheimer's disease at 25 years | Q26749528 | ||
| Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 | Q26801629 | ||
| The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease | Q28005463 | ||
| Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide | Q28131750 | ||
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease | Q29617286 | ||
| Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study | Q30529034 | ||
| Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease | Q30557788 | ||
| The A4 study: stopping AD before symptoms begin? | Q33725775 | ||
| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 | ||
| An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease | Q34364368 | ||
| The preclinical Alzheimer cognitive composite: measuring amyloid-related decline | Q34422469 | ||
| Report of the task force on designing clinical trials in early (predementia) AD. | Q34555301 | ||
| The evolution of preclinical Alzheimer's disease: implications for prevention trials | Q34849048 | ||
| Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease | Q35284971 | ||
| Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument | Q35418054 | ||
| Tau positron emission tomographic imaging in aging and early Alzheimer disease | Q36535275 | ||
| ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials | Q37235850 | ||
| Plasma tau in Alzheimer disease | Q37384690 | ||
| Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons | Q38727771 | ||
| Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. | Q38933111 | ||
| The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model | Q39432793 | ||
| A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease | Q47107905 | ||
| An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. | Q47393680 | ||
| Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis | Q47572013 | ||
| Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease | Q48243501 | ||
| Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic | Q49135523 | ||
| High performance plasma amyloid-β biomarkers for Alzheimer's disease | Q50107488 | ||
| Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. | Q52714704 | ||
| Slowing the progression of Alzheimer disease: methodologic issues. | Q53327604 | ||
| Alzheimer's disease | Q60313667 | ||
| The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's | Q89334340 | ||
| P433 | issue | 2 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 99-106 | |
| P577 | publication date | 2019-02-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention | |
| P478 | volume | 33 |
| Q101146095 | The AT(N) framework for Alzheimer's disease in adults with Down syndrome | cites work | P2860 |
Search more.